Skip to search formSkip to main contentSkip to account menu

GSK 2334470

Known as: GSK-2334470, GSK2334470 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

IndazolesPyrimidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P3-03-05: PI3K/PDK1 mediates resistance to CDK4/6 inhibitors through dysregulation of S-phase cyclins/cyclin dependent kinases (CDKs)
Background: CDK4/6 inhibitors in combination with antiestrogens are approved for the treatment of ER+ advanced breast cancer… 
2016
2016
Abstract PD2-06: Inhibition of 3-phosphoinositide dependent protein kinase 1 (PDK1) synergizes with CDK4/6 inhibitors against ER-positive breast cancer
Background: Dysregulation in cell cycle checkpoints is common in cancer. Small molecule inhibitors that target the CDK4/6… 
2014
2014
The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01, induces fragmentation: possible role of metalloproteinases.
2014
2014
Abstract 59: PDK1 in melanoma development and metastasis
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Phosphoinositide-dependent kinase-1 (PDK-1) is a serine… 
2010
2010
Abstract LB-42: PDK1 knockdown selectively inhibits growth of cancer cells harboring activating mutations involved in MAPK signaling
Phosphoinositide-dependent protein kinase-1 (PDK1) is a master regulator of the AGC family of kinases and an integral component… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)